VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Subjects must have received no more than 2 prior   │ Subjects must have received no more than 2 prior   │     100 │
│ systemic therapies for lymphoma. Prior therapy     │ systemic therapies for lymphoma. Prior therapy     │         │
│ with systemic rituximab monotherapy or             │ with systemic rituximab monotherapy or             │         │
│ conventional chemotherapy (i.e. bendamustine, CVP  │ conventional chemotherapy (i.e. bendamustine, CVP  │         │
│ (Cyclophosphamide, Vincristine Sulfate,            │ (Cyclophosphamide, Vincristine Sulfate,            │         │
│ Prednisone) or other) ± rituximab for indolent     │ Prednisone) or other) ± rituximab for indolent     │         │
│ non-Hodgkin's lymphoma (NHL) ±                     │ non-Hodgkin's lymphoma (NHL) ±                     │         │
│ maintenance/extended-use rituximab will count as 1 │ maintenance/extended-use rituximab will count as 1 │         │
│ line of systemic therapy                           │ line of systemic therapy                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Eastern Cooperative Oncology Group (ECOG)          │ Eastern Cooperative Oncology Group (ECOG)          │     100 │
│ Performance status ≤ 2                             │ Performance status ≤ 2                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects must have normal organ and marrow         │ Subjects must have normal organ and marrow         │     100 │
│ function as defined below                          │ function as defined below                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemoglobin ≥ 8.0 g/dl                              │ Hemoglobin ≥ 8.0 g/dl                              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absolute neutrophil count ≥ 1,000/mcL              │ Absolute neutrophil count ≥ 1,000/mcL              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Platelet count ≥ 75,000/mcL                        │ Platelet count ≥ 75,000/mcL                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Total bilirubin ≤ 1.5 X the upper limit of normal  │ Total bilirubin ≤ 1.5 X the upper limit of normal  │     100 │
│ (ULN) unless a known history of impaired bilirubin │ (ULN) unless a known history of impaired bilirubin │         │
│ conjugation such as Gilbert's, for whom the        │ conjugation such as Gilbert's, for whom the        │         │
│ maximum will be 2.5 ULN                            │ maximum will be 2.5 ULN                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Aspartate transaminase (AST) (SGOT) ≤ 2.5 X        │ Aspartate transaminase (AST) (SGOT) ≤ 2.5 X        │     100 │
│ institutional ULN                                  │ institutional ULN                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Alanine transaminase (ALT) (SGPT) ≤ 2.5 X          │ Alanine transaminase (ALT) (SGPT) ≤ 2.5 X          │     100 │
│ institutional ULN                                  │ institutional ULN                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients must have a calculated serum creatinine   │ Patients must have a calculated serum creatinine   │     100 │
│ clearance \> 50 mL/min using Cockcroft-Gault       │ clearance > 50 mL/min using Cockcroft-Gault        │         │
│ calculation or based on 24-hour urine collection   │ calculation or based on 24-hour urine collection   │         │
│ performed within 7 days prior to treatment         │ performed within 7 days prior to treatment         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Specific guidelines will be followed regarding     │ Specific guidelines will be followed regarding     │     100 │
│ inclusion of relapsed/refractory DLBCL based on    │ inclusion of relapsed/refractory DLBCL based on    │         │
│ Hepatitis B serological testing as follow          │ Hepatitis B serological testing as follow          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HBsAg negative, HBcAb negative, HBsAb positive     │ HBsAg negative, HBcAb negative, HBsAb positive     │     100 │
│ patients are eligible                              │ patients are eligible                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who test positive for HBsAg are           │ Patients who test positive for HBsAg are           │     100 │
│ ineligible                                         │ ineligible                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with HBsAg negative, but HBcAb positive   │ Patients with HBsAg negative, but HBcAb positive   │     100 │
│ (regardless of HBsAb status) should have a HBV DNA │ (regardless of HBsAb status) should have a HBV DNA │         │
│ testing performed and protocol eligibility         │ testing performed and protocol eligibility         │         │
│ determined as follow                               │ determined as follow                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ If HBV DNA is positive, the subject is ineligible  │ If HBV DNA is positive, the subject is ineligible  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ If HBV DNA is negative, the subject may be         │ If HBV DNA is negative, the subject may be         │     100 │
│ included but must undergo HBV DNA PCR testing      │ included but must undergo HBV DNA PCR testing      │         │
│ monthly x 3 months beginning from the start of     │ monthly x 3 months beginning from the start of     │         │
│ treatment                                          │ treatment                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects must have the ability to understand and   │ Subjects must have the ability to understand and   │     100 │
│ the willingness to sign a written informed consent │ the willingness to sign a written informed consent │         │
│ document                                           │ document                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For women of childbearing potential: agreement to  │ For women of childbearing potential: agreement to  │     100 │
│ remain abstinent (refrain from heterosexual        │ remain abstinent (refrain from heterosexual        │         │
│ intercourse) or use a contraceptive method with a  │ intercourse) or use a contraceptive method with a  │         │
│ failure rate of \< 1% per year during the          │ failure rate of < 1% per year during the treatment │         │
│ treatment period and for at least 30 days after    │ period and for at least 30 days after the last     │         │
│ the last dose of venetoclax or 18 months after the │ dose of venetoclax or 18 months after the last     │         │
│ last dose of rituximab, whichever is longer        │ dose of rituximab, whichever is longer             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A woman is considered to be of childbearing        │ A woman is considered to be of childbearing        │     100 │
│ potential if she is postmenarcheal, has not        │ potential if she is postmenarcheal, has not        │         │
│ reached a postmenopausal state (\< 12 continuous   │ reached a postmenopausal state (< 12 continuous    │         │
│ months of amenorrhea with no identified cause      │ months of amenorrhea with no identified cause      │         │
│ other than menopause), and has not undergone       │ other than menopause), and has not undergone       │         │
│ surgical sterilization (removal of ovaries and/or  │ surgical sterilization (removal of ovaries and/or  │         │
│ uterus)                                            │ uterus)                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For men: agreement to remain abstinent (refrain    │ For men: agreement to remain abstinent (refrain    │     100 │
│ from heterosexual intercourse) or use              │ from heterosexual intercourse) or use              │         │
│ contraceptive measures, and agreement to refrain   │ contraceptive measures, and agreement to refrain   │         │
│ from donating sperm, as defined below              │ from donating sperm, as defined below              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ With female partners of childbearing potential,    │ With female partners of childbearing potential,    │     100 │
│ men must remain abstinent or use a condom plus an  │ men must remain abstinent or use a condom plus an  │         │
│ additional contraceptive method that together      │ additional contraceptive method that together      │         │
│ result in a failure rate of \< 1% per year during  │ result in a failure rate of < 1% per year during   │         │
│ the treatment period and for at least 6 months     │ the treatment period and for at least 6 months     │         │
│ after the last dose of rituximab. Men must refrain │ after the last dose of rituximab. Men must refrain │         │
│ from donating sperm during this same period        │ from donating sperm during this same period        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ With pregnant female partners, men must remain     │ With pregnant female partners, men must remain     │     100 │
│ abstinent or use a condom during the treatment     │ abstinent or use a condom during the treatment     │         │
│ period and for at least 6 months after the last    │ period and for at least 6 months after the last    │         │
│ dose of rituximab to avoid exposing the embryo     │ dose of rituximab to avoid exposing the embryo     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects receiving any other investigational       │ Subjects receiving any other investigational       │     100 │
│ agents                                             │ agents                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with active tumor lysis syndrome (TLS)    │ Patients with active tumor lysis syndrome (TLS)    │     100 │
│ either from laboratory or clinical changes         │ either from laboratory or clinical changes         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with active central nervous system (CNS)  │ Patients with active central nervous system (CNS)  │     100 │
│ disease defined as symptomatic meningeal lymphoma  │ disease defined as symptomatic meningeal lymphoma  │         │
│ or known CNS parenchymal lymphoma                  │ or known CNS parenchymal lymphoma                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of severe allergic reactions attributed to │ History of severe allergic reactions attributed to │     100 │
│ compounds of similar chemical or biologic          │ compounds of similar chemical or biologic          │         │
│ composition to rituximab or other agents used in   │ composition to rituximab or other agents used in   │         │
│ this study                                         │ this study                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with uncontrolled intercurrent illness    │ Subjects with uncontrolled intercurrent illness    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HIV-positive subjects on combination               │ HIV-positive subjects on combination               │     100 │
│ antiretroviral therapy are ineligible because of   │ antiretroviral therapy are ineligible because of   │         │
│ the potential for pharmacokinetic interactions     │ the potential for pharmacokinetic interactions     │         │
│ with Venetoclax. In addition, these subjects are   │ with Venetoclax. In addition, these subjects are   │         │
│ at increased risk of lethal infections when        │ at increased risk of lethal infections when        │         │
│ treated with marrow suppressive therapy.           │ treated with marrow suppressive therapy.           │         │
│ Appropriate studies will be undertaken in subjects │ Appropriate studies will be undertaken in subjects │         │
│ receiving combination antiretroviral therapy when  │ receiving combination antiretroviral therapy when  │         │
│ indicated. HIV testing prior to enrollment is not  │ indicated. HIV testing prior to enrollment is not  │         │
│ required for screening but strongly encouraged for │ required for screening but strongly encouraged for │         │
│ patients with no documented prior HIV assessment   │ patients with no documented prior HIV assessment   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of positive test results for hepatitis B  │ Presence of positive test results for hepatitis B  │     100 │
│ virus (HBV), hepatitis B surface antigen (HBsAg),  │ virus (HBV), hepatitis B surface antigen (HBsAg),  │         │
│ or hepatitis C (HCV) antibody                      │ or hepatitis C (HCV) antibody                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are positive for HCV antibody must be │ Patients who are positive for HCV antibody must be │     100 │
│ negative for HCV by polymerase chain reaction      │ negative for HCV by polymerase chain reaction      │         │
│ (PCR) to be eligible for study participation       │ (PCR) to be eligible for study participation       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with occult or prior HBV infection        │ Patients with occult or prior HBV infection        │     100 │
│ (defined as positive total hepatitis B core        │ (defined as positive total hepatitis B core        │         │
│ antibody \[HBcAb\] and negative HBsAg) may be      │ antibody [HBcAb] and negative HBsAg) may be        │         │
│ included if HBV DNA is undetectable. These         │ included if HBV DNA is undetectable. These         │         │
│ patients must be willing to undergo monthly DNA    │ patients must be willing to undergo monthly DNA    │         │
│ testing                                            │ testing                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women who are pregnant or lactating                │ Women who are pregnant or lactating                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Malabsorption syndrome or other condition that     │ Malabsorption syndrome or other condition that     │     100 │
│ precludes enteral route of administration          │ precludes enteral route of administration          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chemotherapy or radiation within 3 weeks of the    │ Chemotherapy or radiation within 3 weeks of the    │     100 │
│ first scheduled study treatment                    │ first scheduled study treatment                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Less than 2-year disease free from another primary │ Less than 2-year disease free from another primary │     100 │
│ malignancy (other than squamous or basal cell      │ malignancy (other than squamous or basal cell      │         │
│ carcinoma of the skin, "in-situ" carcinoma of the  │ carcinoma of the skin, "in-situ" carcinoma of the  │         │
│ cervix or breast, superficial bladder carcinoma,   │ cervix or breast, superficial bladder carcinoma,   │         │
│ or previously treated localized prostate cancer    │ or previously treated localized prostate cancer    │         │
│ with normal prostate specific antigen (PSA)        │ with normal prostate specific antigen (PSA)        │         │
│ levels). Patients who have had completed all anti- │ levels). Patients who have had completed all anti- │         │
│ cancer treatment for another primary malignancy    │ cancer treatment for another primary malignancy    │         │
│ more than 2 years prior to screening are eligible  │ more than 2 years prior to screening are eligible  │         │
│ if they are not considered to have a "currently    │ if they are not considered to have a "currently    │         │
│ active" malignancy based on having less than a 30% │ active" malignancy based on having less than a 30% │         │
│ risk of relapse                                    │ risk of relapse                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Major surgery, other than diagnostic surgery,      │ Major surgery, other than diagnostic surgery,      │     100 │
│ within 2 weeks                                     │ within 2 weeks                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Medical condition requiring chronic use of high    │ Medical condition requiring chronic use of high    │     100 │
│ dose systemic corticosteroids (i.e., doses of      │ dose systemic corticosteroids (i.e., doses of      │         │
│ prednisone higher than 10 mg/day or equivalent).   │ prednisone higher than 10 mg/day or equivalent).   │         │
│ Brief (\<15 days) treatment with glucocorticoids   │ Brief (<15 days) treatment with glucocorticoids    │         │
│ (prednisone 100 mg by mouth daily, or equivalent)  │ (prednisone 100 mg by mouth daily, or equivalent)  │         │
│ is acceptable                                      │ is acceptable                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known allergy to both xanthine oxidase inhibitors  │ Known allergy to both xanthine oxidase inhibitors  │     100 │
│ and rasburicase                                    │ and rasburicase                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of warfarin is prohibited. Anticoagulation     │ Use of warfarin is prohibited. Anticoagulation     │     100 │
│ with low-molecular weight heparin (i.e.            │ with low-molecular weight heparin (i.e.            │         │
│ enoxaparin) or direct thrombin inhibitors is       │ enoxaparin) or direct thrombin inhibitors is       │         │
│ permitted                                          │ permitted                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The following concomitant medications are not      │ The following concomitant medications are not      │     100 │
│ allowed from 7 days prior to the first dose of     │ allowed from 7 days prior to the first dose of     │         │
│ study drug and during venetoclax administration:   │ study drug and during venetoclax administration:   │         │
│ Strong CYP3A4 inhibitors including but not limited │ Strong CYP3A4 inhibitors including but not limited │         │
│ to fluconazole, ketoconazole, and clarithromycin   │ to fluconazole, ketoconazole, and clarithromycin   │         │
│ or strong CYP3A4 inducers included but not limited │ or strong CYP3A4 inducers included but not limited │         │
│ to rifampin, carbamazepine                         │ to rifampin, carbamazepine                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Receipt of live-virus vaccines within 28 days      │ Receipt of live-virus vaccines within 28 days      │     100 │
│ prior to the initiation of study treatment or need │ prior to the initiation of study treatment or need │         │
│ for live-virus vaccines at any time during study   │ for live-virus vaccines at any time during study   │         │
│ treatment                                          │ treatment                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Moderate/Weak CYP3A inducers such as efavirenz and │ Moderate/Weak CYP3A inducers such as efavirenz and │     100 │
│ oxcarbazepine                                      │ oxcarbazepine                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ CYP2C8 substrates such as thiazolidinediones       │ CYP2C8 substrates such as thiazolidinediones       │     100 │
│ (glitazones) and select statins (because of        │ (glitazones) and select statins (because of        │         │
│ expected inhibition of the metabolism of CYP2C8    │ expected inhibition of the metabolism of CYP2C8    │         │
│ substrates) by venetoclax                          │ substrates) by venetoclax                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ CYP2C9 substrates such as tolbutamide (because of  │ CYP2C9 substrates such as tolbutamide (because of  │     100 │
│ expected inhibition of the metabolism of CYP2C9    │ expected inhibition of the metabolism of CYP2C9    │         │
│ substrates by venetoclax. It is recommended to     │ substrates by venetoclax. It is recommended to     │         │
│ exclude CYP2C9 substrates with a narrow            │ exclude CYP2C9 substrates with a narrow            │         │
│ therapeutic index such as phenytoin                │ therapeutic index such as phenytoin                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Histological confirmation of relapsed/refractory   │ Histological confirmation of relapsed/refractory   │      94 │
│ diffuse large B-cell lymphoma after prior          │ diffuse large B-cell lymphoma after prior          │         │
│ rituximab and anthracycline-containing systemic    │ rituximab and anthracycline-containing systemic    │         │
│ treatment regimen such as R-CHOP (rituximab,       │ treatment regimen such as R-CHOP (rituximab,       │         │
│ cyclophosphamide, doxorubicin, vincristine, and    │ cyclophosphamide, doxorubicin, vincristine, and    │         │
│ prednisone), R-EPOCH (rituximab, etoposide         │ prednisone), R-EPOCH (rituximab, etoposide         │         │
│ phosphate, prednisone, vincristine sulfate,        │ phosphate, prednisone, vincristine sulfate,        │         │
│ cyclophosphamide, doxorubicin hydrochloride),      │ cyclophosphamide, doxorubicin hydrochloride),      │         │
│ R-HyperCVAD (rituximab, cyclophosphamide,          │ R-HyperCVAD (rituximab, cyclophosphamide,          │         │
│ vincristine sulfate, doxorubicin hydrochloride,    │ vincristine sulfate, doxorubicin hydrochloride,    │         │
│ dexamethasone) etc. A biopsy immediately before    │ dexamethasone) etc                                 │         │
│ enrollment is not required                         │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HBsAg negative, HBcAb negative, HBsAb negative     │ HBsAg negative, HBcAb negative, HBsAb positive     │      94 │
│ patients are eligible                              │ patients are eligible                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant medications that fall into the         │ Concomitant medications that fall into the         │      97 │
│ categories below could potentially lead to adverse │ categories below could potentially lead to adverse │         │
│ reactions and should be considered with caution    │ reactions and should be considered cautionary      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ International normalized ratio (INR) ≤ 1.5 ×ULN    │ International normalized ratio (INR) > 1.5 ×ULN    │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior treatment toxicities have not resolved to ≤  │ Prior treatment toxicities have not resolved to <  │      99 │
│ Grade 2 according to NCI CTCAE Version 4.0 (except │ Grade 2 according to NCI CTCAE Version 4.0 (except │         │
│ clinically insignificant toxicities such as        │ clinically insignificant toxicities such as        │         │
│ alopecia)                                          │ alopecia)                                          │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                 │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Major surgery, other than diagnostic surgery, │      39 │
│                                   │ within 2 weeks                                │         │
╘═══════════════════════════════════╧═══════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 98.42
OverAll Ratio: 98.71000000000001
